rs121913377
|
|
Carcinogenesis
|
|
0.100 |
GeneticVariation
|
BEFREE |
In particular, evidence for oncogene-induced melanocyte senescence as natural means to prevent tumorigenesis has been obtained in nevi with mutated B-Raf(V600E).
|
18806824 |
2008 |
rs121913377
|
|
Carcinogenesis
|
|
0.100 |
GeneticVariation
|
BEFREE |
The prevalence (90%) of the BRAF (V600E) mutation in this study is the highest ever reported, confirming the key role of this mutation in PTC tumorigenesis.
|
23179992 |
2013 |
rs121913377
|
|
Carcinogenesis
|
|
0.100 |
GeneticVariation
|
BEFREE |
Therefore, these data indicate that PRDX1 and PRDX6 expression not only may play a key role in papillary thyroid carcinogenesis via a BRAF V600E-dependent mechanism, but their determination could be considered as potential tumor marker for indicating tumor progression in PTCs, independently of BRAF status.
|
24316730 |
2014 |
rs121913377
|
|
Carcinogenesis
|
|
0.100 |
GeneticVariation
|
BEFREE |
Here we show decreasing the levels of CTR1 (Cu transporter 1), or mutations in MEK1 that disrupt Cu binding, decreased BRAF(V600E)-driven signalling and tumorigenesis in mice and human cell settings.
|
24717435 |
2014 |
rs121913377
|
|
Carcinogenesis
|
|
0.100 |
GeneticVariation
|
BEFREE |
Thus, this study uncovered a prominent epigenetic mechanism through which BRAF V600E can promote PTC tumorigenesis by altering the methylation and hence the expression of numerous important genes.
|
21937738 |
2011 |
rs121913377
|
|
Carcinogenesis
|
|
0.100 |
GeneticVariation
|
BEFREE |
Interesting, Prof. Peng Hou and colleagues, at the First Affiliated Hospital of Xi'an Jiaotong University in China, identified unknown epigenetic mechanisms and their involvement in the tumorigenesis of B-RAF(V600E)-driven cancer.
|
28638488 |
2017 |
rs121913377
|
|
Carcinogenesis
|
|
0.100 |
GeneticVariation
|
BEFREE |
These data suggest that the BRAF V600E mutation is not the target gene for abnormal MMR in carcinogenesis in patients with sporadic endometrial cancer, unlike in colon cancer.
|
19424571 |
2009 |
rs121913377
|
|
Carcinogenesis
|
|
0.100 |
GeneticVariation
|
BEFREE |
Aberrant signaling of the Ras-Raf-MEK-ERK (MAP kinase) pathway driven by the mutant kinase BRAF(V600E), as a result of the BRAF(T1799A) mutation, plays a fundamental role in thyroid tumorigenesis.
|
21185263 |
2011 |
rs121913377
|
|
Carcinogenesis
|
|
0.100 |
GeneticVariation
|
BEFREE |
We propose that continuously activated BRAF(V600E) signaling may be a possible mechanism for the deregulation of Mps1 stability and kinase activity in human tumors, and that persistent phosphorylation of Mps1 through BRAF(V600E) signaling is a key event in disrupting the control of centrosome duplication and chromosome stability that may contribute to tumorigenesis.
|
22430208 |
2013 |
rs121913377
|
|
Carcinogenesis
|
|
0.100 |
GeneticVariation
|
BEFREE |
We combined (L597V)Braf with (G12D)Kras and found that (L597V)Braf modified (G12D)Kras oncogenesis such that fibroblast transformation and lung tumor development were more reminiscent of that driven by the high-activity (V600E)Braf mutant.
|
22892241 |
2012 |
rs121913377
|
|
Carcinogenesis
|
|
0.100 |
GeneticVariation
|
BEFREE |
To determine the occurrence of BRAF V600E gene mutations and copy number changes of all autosome arms and genes known to be frequently altered in tumorigenesis in primary and metastatic conjunctival melanomas (CoMs).
|
21693616 |
2011 |
rs121913377
|
|
Carcinogenesis
|
|
0.100 |
GeneticVariation
|
BEFREE |
While the role of BRAF(V600E) in tumorigenesis is well established, its involvement in metastasis that is clinically observed in melanoma patients remains a topic of debate.
|
27210749 |
2016 |
rs121913377
|
|
Carcinogenesis
|
|
0.100 |
GeneticVariation
|
BEFREE |
A large number of studies in the past decade have tried to dissect the relevance and the function of the V600E mutation in controlling oncogenesis and progression of thyroid cancer.
|
24828987 |
2015 |
rs121913377
|
|
Carcinogenesis
|
|
0.100 |
GeneticVariation
|
BEFREE |
Distribution of BRAF T1799A(V600E) mutations across various types of benign nevi: implications for melanocytic tumorigenesis.
|
18032947 |
2007 |
rs121913377
|
|
Carcinogenesis
|
|
0.100 |
GeneticVariation
|
BEFREE |
The paradoxically higher incidence of BRAF(V600E) mutations in medium-sized compared with giant CMNs suggests that the presence of the BRAF(V600E) mutation may play different roles between medium and giant CMNs in melanocytic tumorigenesis.
|
21430505 |
2011 |
rs121913377
|
|
Carcinogenesis
|
|
0.100 |
GeneticVariation
|
BEFREE |
Here we report that BRAF(V600E) expression in neural progenitors (NPs) is insufficient for tumorigenesis and increases NP cellular differentiation as well as apoptosis.
|
22586120 |
2012 |
rs121913377
|
|
Carcinogenesis
|
|
0.100 |
GeneticVariation
|
BEFREE |
The high frequency of methylation and BRAF V600E mutation suggests that many signet ring cell carcinomas may be related to the serrated pathway of carcinogenesis.
|
22522845 |
2012 |
rs121913377
|
|
Carcinogenesis
|
|
0.100 |
GeneticVariation
|
BEFREE |
This is the first report of BRAF V600E mutation in endometrial cancer, indicating that it may contribute to tumorigenesis of endometrial cancer, although at a low frequency compared with KRAS mutations.
|
23370429 |
2013 |
rs121913377
|
|
Carcinogenesis
|
|
0.100 |
GeneticVariation
|
BEFREE |
The coexistence of LCH and ECD in the same biopsy and the BRAF (V600E) mutation status in both histologic types support the recent re-classification of the histiocytic disorder into LCH, ECD, and "mixed histiocytosis", which reflects tumorigenesis for all three from a common progenitor cell.
|
26466952 |
2016 |
rs121913377
|
|
Carcinogenesis
|
|
0.100 |
GeneticVariation
|
BEFREE |
The data suggest that coexpression of BRAF(V600E) and KRAS(G12D) in early tumorigenesis leads to negative selection due to oncogene-induced senescence.
|
26028035 |
2016 |
rs121913377
|
|
Carcinogenesis
|
|
0.100 |
GeneticVariation
|
BEFREE |
According to the literature, our data provide evidence of the BRAF and RAS roles in thyroid tumorigenesis, supporting an association between BRAF (V600E) mutations and the more aggressive clinical and pathological features of thyroid tumors.
|
29435002 |
2018 |
rs121913377
|
|
Carcinogenesis
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF(V600E) mutation is an early event in thyroid carcinogenesis, and is associated with distinctive morphology and aggressive features even in papillary thyroid microcarcinomas.
|
22918165 |
2013 |
rs121913377
|
|
Carcinogenesis
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our findings provide a molecular linkage between the LKB1-AMPK and the RAF-MEK-ERK pathways and suggest that suppression of LKB1 function by B-RAF V600E plays an important role in B-RAF V600E-driven tumorigenesis.
|
19187764 |
2009 |
rs121913377
|
|
Carcinogenesis
|
|
0.100 |
GeneticVariation
|
BEFREE |
Specifically, both the initial and recurrent tumors of the patient showed the same BRAF V600E mutation, which refutes previous suggestions that BRAF mutations may be limited to intracranial PXAs and also shows that BRAF mutations may occur earlier in PXA tumorigenesis.
|
27956254 |
2017 |
rs121913377
|
|
Carcinogenesis
|
|
0.100 |
GeneticVariation
|
BEFREE |
Mutation in the B RAF at V600E has been well implicated in the carcinogenesis that makes it as an attractive therapeutictarget.
|
28472910 |
2017 |